Flavopiridol: Where do we stand in chronic lymphocytic leukemia?

Leukemia

Volumn 18, Issue 2, 2004, Pages 243-246

  Lin, T S ^a   Porcu, P ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; CYTARABINE; FLAVOPIRIDOL; FLUDARABINE; NITRIC OXIDE SYNTHASE; PACLITAXEL; PROTEIN BCL 2; PROTEIN P53; RITUXIMAB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER SURVIVAL; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE DELETION; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL;

EID: 1242307371     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403237     Document Type: Article

References (48)

1. kip1 in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 2003; 17: 2435-2443.
2. Grever MR, Leiby J, Kraut E, Metz E, Neidhart J, Balcerzak S et al. A comprehensive phase I and II clinical investigation of fludarabine phosphate. Semin Oncol 1990; 17 (Suppl 8): 39-48.
3. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller CA, Barlogie B. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19-25.
4. Keating MJ, Kantarjian H, O'Brien S, Koller CA, Talpaz M, Schachner J et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 44-49.
5. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller CA et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878-2884.
6. Keating MJ, O'Brien S, Lerner S, Koller CA, Beran M, Robertson LE et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165-1171.
7. Boogaerts MA, Van Hoof A, Catovsky D, Kovacs M, Montillo M, Zinzani PL. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 4252-4258.
8. Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96: 71-75.
9. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414-1420.
10. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379-3389.
11. Pepper C, Thomas A, Hidalgo de Quintana J, Davies S, Hoy T, Bentley P. Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia: the role of Bcl-2 family dysregulation. Leukemia Res 1999; 23: 1007-1014.
12. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-3908.
13. Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001; 24: 263-271.
14. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson MD, Lucas D et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99: 1038-1043.
15. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002; 99: 1314-1319.
16. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56: 2973-2978.
17. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek HH, Myers C et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992; 84: 1736-1740.
18. Sausville EA, Johnson J, Alley M, Zaharevitz D, Senderowicz AM. Inhibition of CDKs as a therapeutic modality. Ann N Y Acad Sci 2000; 910: 207-222.
19. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000; 92: 376-387.
20. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92: 3804-3816.
21. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998; 91: 458-465.
22. Pepper C, Thomas A, Hoy T, Tighe J, Culligan D, Fegan C. Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol. Cell Cycle 2003; 2: 53-58.
23. Pepper C, Thomas A, Hoy T, Fegan C, Bentley P. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol 2001; 114: 70-77.
24. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 393-397.
25. Zhao H, Dugas N, Mathiot C, Dugas B, Sigaux F, Kolb J-P. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 1998; 92: 1031-1043.
26. kip1 in chronic lymphocytic leukemia. Blood 1998; 91: 4694-4700.
27. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/ MDR3 gene expression. Blood 1993; 82: 3452-3459.
28. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-3157.
29. Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker for disease progression and poor prognosis. Blood 1998; 91: 4342-4349.
30. Stilgenbauer S. Genomic aberrations, p53 abnormalities, and IgV mutation: relationship to disease evolution, resistance to therapy, and clinical course of CLL. Leukemia Lymphoma 2000; 42: 1-2.
31. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
32. Delia D, Mizutani S, Panigone S, Tagliabue E, Fontanella E, Asada M. ATM protein and p53-serine 15 phosphorylation in ataxia-telangiectasia (AT) patients and AT heterozygotes. Br J Cancer 2000; 82: 1938-1945.
33. Pandita TK, Lieberman HB, Lim DS, Dhar S, Zheng W, Taya Y et al. Ionizing radiation activates the ATM kinase throughout the cell cycle. Oncogene 2000; 19: 1386-1391.
34. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998; 281: 1677-1679.
35. Takao N, Li Y, Yamamoto K. Protective roles for ATM in cellular response to oxidative stress. FEBS Lett 2000; 472: 133-136.
36. Morrison C, Sonoda E, Takao N, Shinohara A, Yamamoto K, Takeda S. The controlling role of ATM in homologous recombinational repair of DNA damage. EMBO J 2000; 19: 463-471.
37. Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, Byrd PJ et al. Inactivation of ataxia telengiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999; 353: 26-29.
38. Bullrich F, Rasio D, Kitada S, Starostik P, Kipps T, Keating MJ et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 1999; 59: 24-27.
39. Starostik P, Manshouri T, O'Brien S, Freireich EJ, Kantarjian H, Haidar M. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res 1998; 58: 4552-4557.
40. Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 748-753.
41. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 14-22.
42. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16: 2986-2999.
43. Lin TS, Howard OM, Neuberg DS, Kim HH, Shipp MA. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leukemia Lymphoma 2002; 43: 793-797.
44. Innocenti F, Stadler WM, Iyer L, Ramirez J, Vokes EE, Ratain MJ. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res 2000; 6: 3400-3405.
45. Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001; 7: 1590-1599.
46. Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001; 19: 1985-1992.
47. Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago phase II consortium study. J Clin Oncol 2000; 18: 371-375.
48. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997; 57: 3375-3380.